JP2021512099A5 - - Google Patents
Info
- Publication number
- JP2021512099A5 JP2021512099A5 JP2020541689A JP2020541689A JP2021512099A5 JP 2021512099 A5 JP2021512099 A5 JP 2021512099A5 JP 2020541689 A JP2020541689 A JP 2020541689A JP 2020541689 A JP2020541689 A JP 2020541689A JP 2021512099 A5 JP2021512099 A5 JP 2021512099A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- ttds
- palm
- amino acid
- stea
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18305094 | 2018-01-31 | ||
| EP18305094.7 | 2018-01-31 | ||
| PCT/EP2019/052298 WO2019149782A1 (en) | 2018-01-31 | 2019-01-30 | Modified lipidated relaxin b chain peptides and their therapeutic use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021512099A JP2021512099A (ja) | 2021-05-13 |
| JP2021512099A5 true JP2021512099A5 (enExample) | 2022-02-02 |
| JP7295871B2 JP7295871B2 (ja) | 2023-06-21 |
Family
ID=61223862
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020541689A Active JP7295871B2 (ja) | 2018-01-31 | 2019-01-30 | 修飾された脂質化リラキシンｂ鎖ペプチドおよびその治療的使用 |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US10961295B2 (enExample) |
| EP (1) | EP3746467B1 (enExample) |
| JP (1) | JP7295871B2 (enExample) |
| KR (1) | KR102755938B1 (enExample) |
| CN (1) | CN111770934B (enExample) |
| AR (1) | AR114325A1 (enExample) |
| AU (1) | AU2019214358B2 (enExample) |
| BR (1) | BR112020014834A2 (enExample) |
| CA (1) | CA3089657A1 (enExample) |
| CO (1) | CO2020008308A2 (enExample) |
| DK (1) | DK3746467T3 (enExample) |
| ES (1) | ES3058633T3 (enExample) |
| FI (1) | FI3746467T3 (enExample) |
| HR (1) | HRP20260016T1 (enExample) |
| IL (2) | IL316406A (enExample) |
| LT (1) | LT3746467T (enExample) |
| MA (1) | MA52994A (enExample) |
| MX (1) | MX2020008096A (enExample) |
| MY (1) | MY199821A (enExample) |
| NZ (1) | NZ766762A (enExample) |
| PH (1) | PH12020551118A1 (enExample) |
| PL (1) | PL3746467T3 (enExample) |
| PT (1) | PT3746467T (enExample) |
| RS (1) | RS67606B1 (enExample) |
| SG (1) | SG11202006903WA (enExample) |
| SI (1) | SI3746467T1 (enExample) |
| TW (1) | TWI763972B (enExample) |
| UY (1) | UY38069A (enExample) |
| WO (1) | WO2019149782A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20191716A1 (es) | 2017-02-08 | 2019-12-05 | Bristol Myers Squibb Co | Polipeptidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos |
| WO2019149781A1 (en) * | 2018-01-31 | 2019-08-08 | Sanofi | Modified lipidated relaxin b chain peptides and their therapeutic use |
| NZ766762A (en) | 2018-01-31 | 2026-03-27 | Sanofi Sa | Modified lipidated relaxin b chain peptides and their therapeutic use |
| CA3204051A1 (en) | 2021-01-20 | 2022-07-28 | Brian Lian | Compositions and methods for the treatment of metabolic and liver disorders |
| AU2022334113A1 (en) * | 2021-08-23 | 2024-03-14 | River 2 Renal Corp. | Combination of relaxin and vasopressin analogues for treatment of renal disorders or conditions |
| JP7642830B2 (ja) | 2021-09-15 | 2025-03-10 | バイキング・セラピューティクス・インコーポレイテッド | 代謝及び肝臓障害の処置のための組成物及び方法 |
| CN118510536A (zh) | 2021-11-11 | 2024-08-16 | 泰克托尼治疗股份有限公司 | 松弛素-2融合蛋白类似物及其使用方法 |
| CN115998842B (zh) * | 2022-09-02 | 2025-08-26 | 郑州大学第一附属医院 | 一种逆转肝星形细胞激活的仿生纳米药物及其应用 |
| AU2024270919A1 (en) | 2023-05-18 | 2026-01-15 | Tectonic Operating Company, Inc. | Relaxin-2 fusion protein analogs and methods of using same |
| KR20250054870A (ko) * | 2023-10-16 | 2025-04-24 | (주)케어젠 | 피부 상태 개선 활성을 갖는 펩타이드 및 이의 용도 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102348723A (zh) * | 2008-12-05 | 2012-02-08 | 安吉奥开米公司 | 肽治疗剂轭合物及其应用 |
| EP2460527A1 (en) * | 2010-01-21 | 2012-06-06 | Sanofi | Pharmaceutical composition for treating a metabolic syndrome |
| EP2524915A1 (en) * | 2011-05-20 | 2012-11-21 | Sanofi | 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors |
| TW201315739A (zh) * | 2011-07-01 | 2013-04-16 | 拜耳智慧財產有限公司 | 鬆弛素（ｒｅｌａｘｉｎ）融合多肽類及其用途 |
| RU2014103288A (ru) * | 2011-07-01 | 2015-08-10 | Байер Интеллектчуал Проперти Гмбх | Слитые полипептиды релаксина и их применение |
| JP6276690B2 (ja) * | 2011-08-04 | 2018-02-07 | ファリス バイオテック ゲーエムベーハー | ヒトリラキシン−２を調製する方法 |
| WO2013177529A1 (en) * | 2012-05-24 | 2013-11-28 | Angion Biomedica Corp. | Relaxin-like compounds and uses thereof |
| JP6822839B2 (ja) | 2013-09-13 | 2021-01-27 | ザ・スクリップス・リサーチ・インスティテュート | 修飾された治療剤、及びその組成物 |
| EP3131925B1 (en) | 2014-04-17 | 2020-02-19 | The Florey Institute of Neuroscience and Mental Health | Modified relaxin b chain peptides |
| JP2017513875A (ja) * | 2014-04-22 | 2017-06-01 | ティーエックスピー ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 分枝状アミノ酸プローブを有するペプチド類似体 |
| PE20191716A1 (es) * | 2017-02-08 | 2019-12-05 | Bristol Myers Squibb Co | Polipeptidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos |
| TW201934572A (zh) | 2018-01-31 | 2019-09-01 | 法商賽諾菲公司 | 經修飾之鬆弛素ｂ鏈胜肽及其治療用途 |
| WO2019149781A1 (en) * | 2018-01-31 | 2019-08-08 | Sanofi | Modified lipidated relaxin b chain peptides and their therapeutic use |
| NZ766762A (en) | 2018-01-31 | 2026-03-27 | Sanofi Sa | Modified lipidated relaxin b chain peptides and their therapeutic use |
| TWI844709B (zh) * | 2019-07-31 | 2024-06-11 | 美商美國禮來大藥廠 | 鬆弛素(relaxin)類似物及其使用方法 |
| AU2022334113A1 (en) * | 2021-08-23 | 2024-03-14 | River 2 Renal Corp. | Combination of relaxin and vasopressin analogues for treatment of renal disorders or conditions |
-
2019
- 2019-01-30 NZ NZ766762A patent/NZ766762A/en unknown
- 2019-01-30 MY MYPI2020003535A patent/MY199821A/en unknown
- 2019-01-30 WO PCT/EP2019/052298 patent/WO2019149782A1/en not_active Ceased
- 2019-01-30 KR KR1020207020681A patent/KR102755938B1/ko active Active
- 2019-01-30 EP EP19702593.5A patent/EP3746467B1/en active Active
- 2019-01-30 DK DK19702593.5T patent/DK3746467T3/da active
- 2019-01-30 BR BR112020014834-2A patent/BR112020014834A2/pt unknown
- 2019-01-30 LT LTEPPCT/EP2019/052298T patent/LT3746467T/lt unknown
- 2019-01-30 PL PL19702593.5T patent/PL3746467T3/pl unknown
- 2019-01-30 FI FIEP19702593.5T patent/FI3746467T3/fi active
- 2019-01-30 HR HRP20260016TT patent/HRP20260016T1/hr unknown
- 2019-01-30 IL IL316406A patent/IL316406A/en unknown
- 2019-01-30 RS RS20260005A patent/RS67606B1/sr unknown
- 2019-01-30 ES ES19702593T patent/ES3058633T3/es active Active
- 2019-01-30 IL IL276170A patent/IL276170B2/en unknown
- 2019-01-30 JP JP2020541689A patent/JP7295871B2/ja active Active
- 2019-01-30 CN CN201980015588.9A patent/CN111770934B/zh active Active
- 2019-01-30 SI SI201931009T patent/SI3746467T1/sl unknown
- 2019-01-30 CA CA3089657A patent/CA3089657A1/en active Pending
- 2019-01-30 MX MX2020008096A patent/MX2020008096A/es unknown
- 2019-01-30 MA MA052994A patent/MA52994A/fr unknown
- 2019-01-30 AU AU2019214358A patent/AU2019214358B2/en active Active
- 2019-01-30 SG SG11202006903WA patent/SG11202006903WA/en unknown
- 2019-01-30 PT PT197025935T patent/PT3746467T/pt unknown
- 2019-01-31 TW TW108103457A patent/TWI763972B/zh active
- 2019-01-31 US US16/264,643 patent/US10961295B2/en active Active
- 2019-01-31 UY UY38069A patent/UY38069A/es not_active Application Discontinuation
- 2019-01-31 AR ARP190100222A patent/AR114325A1/es unknown
-
2020
- 2020-07-06 CO CONC2020/0008308A patent/CO2020008308A2/es unknown
- 2020-07-22 PH PH12020551118A patent/PH12020551118A1/en unknown
- 2020-10-30 US US17/086,183 patent/US11725036B2/en active Active
-
2023
- 2023-06-26 US US18/341,320 patent/US20240218042A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021512099A5 (enExample) | ||
| FI3746467T3 (fi) | Muutetut lipidoidut relaksiinin b-ketjun peptidit ja niiden terapeuttinen käyttö | |
| JP2020073472A5 (enExample) | ||
| JP2014509838A5 (enExample) | ||
| EP2858661B1 (en) | Stabilized antiviral fusion helices | |
| JP2020502051A5 (enExample) | ||
| JP6633523B2 (ja) | Ｐｓｄ−９５の二量体阻害剤脂肪酸誘導体 | |
| JP2010535714A5 (enExample) | ||
| JP2010502734A5 (enExample) | ||
| JP2024532403A5 (enExample) | ||
| JP2012211164A5 (enExample) | ||
| JP2012531219A5 (enExample) | ||
| JP2011525190A5 (enExample) | ||
| JP2009108078A5 (enExample) | ||
| JP2015534972A5 (enExample) | ||
| JP2023502005A5 (enExample) | ||
| CN1662551A (zh) | 前列腺素e2受体亚型ep4的拮抗肽 | |
| JP2023551122A5 (enExample) | ||
| JP2024532403A (ja) | 腎障害または状態の治療のためのリラキシン類似体とバソプレシン類似体との組み合わせ | |
| JP2018536645A5 (enExample) | ||
| JP2018526987A5 (enExample) | ||
| JP2018507187A5 (enExample) | ||
| JP2024539138A5 (enExample) | ||
| JP3221881B2 (ja) | Ｃ反応性タンパク質断片から誘導されたオリゴペプチド | |
| IL299778A (en) | Therapeutic use of glucagon derivative or conjugate thereof for liver disease |